MDxHealth S.A. (MDXH) Stock Score, Valuation & Financial Research
MDxHealth S.A. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for MDXH
MDxHealth S.A. currently has a Wall Street Score of 23/100. The stored market price is $0.68. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What MDxHealth S.A. does
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
MDXH financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $0.68
- Market capitalization:
- $35.0M
- Revenue:
- $171.3M
- Net income:
- $-64.2M
- Free cash flow:
- $-11.6M
- Cash:
- $29.0M
- Total debt:
- $95.1M
- EPS:
- -0.67
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 59/100
What stands out
- Reported year-over-year revenue growth is +0.6%.
- Free cash flow is $-11.6M, showing cash burn in the current stored period.
- The balance sheet shows $29.0M of cash versus $95.1M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MDXH
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.